Maxalt en es it fr

Maxalt Brand names, Maxalt Analogs

Maxalt Brand Names Mixture

  • No information avaliable

Maxalt Chemical_Formula


Maxalt RX_link

Maxalt fda sheet

Maxalt FDA

Maxalt msds (material safety sheet)

Maxalt MSDS

Maxalt Synthesis Reference

No information avaliable

Maxalt Molecular Weight

269.345 g/mol

Maxalt Melting Point

178-180 oC

Maxalt H2O Solubility

42 mg/mL (for free base)

Maxalt State


Maxalt LogP


Maxalt Dosage Forms

Tablet; Wafer

Maxalt Indication

For treatment of acute migraine attacks.

Maxalt Pharmacology

Rizatriptan is a selective 5-hydroxytryptamine receptor subtype agonist indicated for the acute treatment of migraine attacks with or without aura in adults. Rizatriptan is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine. Rizatriptan is an agonist for a vascular 5-hydroxytryptamine receptor subtype (probably a member of the 5-HT1D family) having only a weak affinity for 5-HT1A, 5-HT5A, and 5-HT7 receptors and no significant affinity or pharmacological activity at 5-HT2, 5-HT3 or 5-HT4 receptor subtypes or at alpha1-, alpha2-, or beta-adrenergic, dopamine1,; dopamine2; muscarinic, or benzodiazepine receptors. This action in humans correlates with the relief of migraine headache. In addition to causing vasoconstriction, experimental data from animal studies show that Rizatriptan also activates 5-HT1 receptors on peripheral terminals of the trigeminal nerve innervating cranial blood vessels, which may also contribute to the antimigrainous effect of Rizatriptan in humans.

Maxalt Absorption

Rapid following oral administration. Bioavailability is 45%. Food has no effect on the bioavailability of rizatriptan. However, administering rizatriptan with food will delay by 1 hour the time to reach peak plasma concentration. The rate of absorption is not affected by the presence of a migraine attack.

Maxalt side effects and Toxicity

Symptoms of overdose include dizziness, fainting, heart and blood vessel problems, high blood pressure, loss of bowel and bladder control, slow heartbeat, and vomiting.

Maxalt Patient Information

Migraine or treatment with MAXALT may cause somnolence in some patients. Dizziness has also been reported in some patients receiving MAXALT. Patients should, therefore, evaluate their ability to perform complex tasks during migraine attacks and after administration of MAXALT. Physicians should instruct their patients to read the patient package insert before taking MAXALT.

Maxalt Organisms Affected

Humans and other mammals